XORTX Therapeutics (XRTX) versus Its Competitors Financial Survey

XORTX Therapeutics (NASDAQ:XRTX) is one of 247 publicly-traded companies in the “MED – DRUGS” industry, but how does it weigh in compared to its peers? We will compare XORTX Therapeutics to related companies based on the strength of its risk, valuation, dividends, earnings, profitability, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares XORTX Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XORTX Therapeutics	N/A	-$2.66 million	-1.01
XORTX Therapeutics Competitors	$1.17 billion	$98.20 million	-4.51

XORTX Therapeutics’ peers have higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares XORTX Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-120.32%	-90.53%
XORTX Therapeutics Competitors	-22,657.44%	-150.65%	-22.79%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for XORTX Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1	0	0	0	1.00
XORTX Therapeutics Competitors	2885	4050	10322	468	2.47

As a group, “MED – DRUGS” companies have a potential upside of 55.14%. Given XORTX Therapeutics’ peers stronger consensus rating and higher probable upside, analysts clearly believe XORTX Therapeutics has less favorable growth aspects than its peers.

Volatility and Risk

XORTX Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, XORTX Therapeutics’ peers have a beta of -0.38, meaning that their average stock price is 138% less volatile than the S&P 500.

Insider & Institutional Ownership

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 43.9% of shares of all “MED – DRUGS” companies are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

XORTX Therapeutics peers beat XORTX Therapeutics on 9 of the 13 factors compared.

XORTX Therapeutics Company Profile

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.